House Bill No. [insert bill number] amends R.S. 22:1076.1 to revise the composition and operational procedures of the advisory board responsible for recommending new treatments for rare cancers. The bill increases the number of oncologists on the board from two to four, resulting in a total of seventeen members. Additionally, it specifies that the chairperson will be the executive director or designee of the Louisiana Cancer Research Center.

The bill also modifies the reporting requirements for the advisory board, extending the deadline for submitting formal written reports from thirty to forty-five days after each meeting. These reports will now be submitted to the House Committee on Insurance and the Senate Committee on Insurance, rather than the legislature as a whole. The advisory board is still required to hold quarterly public meetings unless otherwise decided by a vote or order from the chairperson, and the commissioner retains the authority to promulgate necessary administrative rules.

Statutes affected:
HB761 Original: